Physician profile
Deep Patadia
NPI 1437561339
$1,421.52
in general payments reported to CMS, 2019-2025
15 companies · $58.89 in 2025
The $58.89 reported for 2025 was less than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $483 · 2021: $62.97 · 2022: $271 · 2023: $147 · 2024: $399 · 2025: $58.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $604.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $483.34 | 2019 | |
| Glaxosmithkline, LLC. | $428.75 | 2022-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Amgen INC. | $161.49 | 2022-2025 | Tezspire |
| Abiomed | $60.05 | 2023-2024 | Impella |
| Inquis Medical, INC. | $54.55 | 2024 | |
| Merck Sharp & Dohme LLC | $35.91 | 2022-2024 | Recarbrio, Prevymis, Zerbaxa |
| United Therapeutics Corporation | $29.86 | 2021-2023 | Tyvaso |
| Medtronic, INC. | $26.19 | 2021 | |
| Baxter Healthcare | $23.91 | 2022 | |
| Getinge USA Sales, LLC | $23.06 | 2024 | Cardiohelp |
| Advanced Respiratory, INC | $22.65 | 2021 | |
| Viatris Specialty LLC | $20.91 | 2025 | Yupelri |
| Philips North America LLC | $20.00 | 2023 | |
| Mylan Specialty L.P. | $15.90 | 2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $14.95 | 2024 | Glassia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deep Patadia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.